Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Cognition Therapeutics Q4 2025 Earnings Call - Prioritizing DLB Psychosis for Zervimesine After Strong Phase II Psychosis Signal
Cognition Therapeutics is pivoting to pursue a registration strategy for zervimesine (CT-1812) in dementia with Lewy bodies psychosis, after phase II SHIMMER data showed a pronounced impact on neurops...
- Cognition will prioritize zervimesine (CT-1812, USAN zervimesine) development for dementia with Lewy bodies (DLB) psychosis based on phase II SHIMMER data.
- SHIMMER reported an 86% slowing of progression on the NPI-12 neuropsychiatric scale versus placebo, with the largest effects on hallucinations and delusions (psychosis).
- FDA directed the company to the Division of Psychiatry to define a registration path; a meeting request has been filed and company expects official meeting minutes mid-year.
- +12 more takeaways
Acumen Pharmaceuticals Fourth Quarter 2025 Earnings Call - ALTITUDE-AD Readout Late 2026 and EBD Program Shows 14-40x Brain Uptake
Acumen positions 2026 as make-or-break. The company expects a pivotal readout from its phase II ALTITUDE-AD trial of sabirnetug late this year, while advancing a partnership with JCR that produced pre...
- Acumen expects the phase II ALTITUDE-AD readout for sabirnetug late in 2026, presenting efficacy and safety data that will guide next steps.
- Sabirnetug is an IgG2 monoclonal antibody selectively targeting soluble A-beta oligomers, positioned as potentially higher benefit-risk versus plaque-directed IgG1s.
- Phase Ib INTERCEPT-AD showed early biomarker activity: after three doses at the 3-month timepoint sabirnetug reduced CSF phospho-tau-181 and neurogranin, supportive but not definitive for clinical effect.
- +12 more takeaways
Rockwell Medical Q4 & Full Year 2025 Earnings Call - Operational overhaul drove margin rebound and positive cash flow, positioning firm for modest 2026 profitability
Rockwell Medical closed 2025 after a year of structural change, not miracles. Revenue fell as expected after a large customer cut volumes, but management retooled operations, tightened pricing discipl...
- Q4 2025 net sales were $18.3 million, down 26% year over year from Q4 2024, reflecting a major customer reducing purchase volumes.
- Full year 2025 net sales were $69.3 million, a 32% decline versus 2024, driven primarily by the expected reduction in volumes from one large customer.
- Q4 gross profit was $3.9 million and gross margin rose to 21%, up from 14% in Q3, described as one of the strongest gross margin quarters in company history.
- +15 more takeaways
22nd Century Group Q4 2025 Earnings Call - Transition to Growth; VLN Rollout Live in Retail
22nd Century says 2025 was the reset year and 2026 is the new beginning. Management finished restructuring, paid off long-term debt, completed a financing that takes cash to north of $10 million, and ...
- Company completed restructuring in 2025, exited unprofitable contracts and paid off all long-term debt, resulting in a debt-free capital structure.
- Management closed a financing that raised approximately $5.6 million, putting cash on the balance sheet above $10 million post-close.
- VLN (very low nicotine) combustible cigarette SKUs are now in market: management reports presence in 1,636 retail outlets across 23 states.
- +13 more takeaways
Oportun Financial Q4 2025 Earnings Call - Sustained GAAP Profitability, Lower Cost of Capital, and a Measured Return to Risk-Based Pricing
Oportun closed 2025 with a clear operational pivot. The company delivered full-year GAAP net income of $25 million and a step-up in adjusted EPS, while cutting operating costs, lowering funding costs,...
- Full-year 2025 GAAP net income was $25 million, with Q4 GAAP net income of $3.4 million, capping a year with GAAP net income up $104 million year-over-year.
- Adjusted EPS for full-year 2025 was $1.36, toward the high end of guidance, representing an 89% year-over-year increase in adjusted EPS.
- Q4 annualized net charge-off rate was 12.3%, at the low end of prior guidance, with management expecting Q1 2026 to represent a peak quarterly charge-off near a 12.65% midpoint.
- +17 more takeaways
Ardent Health Fourth Quarter 2025 Earnings Call - IMPACT uplifted to $55M, guiding 2026 adjusted EBITDA $485M-$535M
Ardent closed 2025 with record revenue, EBITDA, and operating cash flow, and management says a newly accelerated IMPACT program is the reason. The company raised its expected IMPACT savings to roughly...
- Ardent reported record 2025 results: full year revenue $6.3 billion (up 6%), adjusted EBITDA $545 million (up 9%), and operating cash flow $471 million (up 49%).
- Fourth quarter revenue was $1.61 billion (essentially flat YoY), and 4Q adjusted EBITDA was $134 million, about 2% above the implied guidance midpoint.
- Management raised the IMPACT program savings target from $40 million to approximately $55 million for 2026, calling IMPACT a multi-year operating model transformation across revenue, expense, agility, and care.
- +13 more takeaways
Gibraltar Industries Fourth Quarter 2025 Earnings Call - OmniMax Deal Recasts Gibraltar into a Residential Powerhouse with $24M Synergies
Gibraltar reported Q4 results in line with prior guidance, finishing 2025 with 12% adjusted revenue growth to $1.14 billion, adjusted EPS of $3.92 for the year, and $137 million in operating cash flow...
- Q4 results were in line with guidance; adjusted Q4 net sales rose 17% year over year, driven by metal roofing and acquisitions, while FY2025 adjusted net sales were $1.14 billion, up 12% versus 2024.
- OmniMax acquisition closed on February 2, 2026, and is expected to contribute roughly $570 million of revenue to 2026, shifting Gibraltar to a business that is over 80% residential in 2026.
- Management increased expected run-rate synergies from $20 million to $24 million, with about $15 million flowing to full-year 2026 EBITDA and the remaining roughly $9 million carried into 2027.
- +17 more takeaways
Hagerty Fourth Quarter 2025 Earnings Call - New Markel Fronting Arrangement Creates 2026 GAAP Noise Despite Strong Underlying Growth
Hagerty closed 2025 with strong top-line and profit momentum, driven by a record 371,000 new members, double-digit premium growth and efficiency gains that lifted full-year net income 91% to $149 mill...
- Record new members: Hagerty added 371,000 new members in 2025, fueling recurring premium growth and ecosystem adoption.
- Strong 2025 financials: Full-year revenue up 17%, net income up 91% to $149 million, and operating cash flow up 24% to $219 million.
- Written premium momentum: Written premiums grew 14% for full year 2025 and 19% in Q4, driven by new business and State Farm ramp.
- +12 more takeaways
Eos Energy Enterprises Q4 2025 Earnings Call - Missed Guidance, Indensity and Automation Roadmap Aim to Deliver 2026 Ramp
Eos closed 2025 with headline wins and an uncomfortable caveat. Revenue exploded to $114.2 million, up more than 7x year over year, and Q4 posted a record $58 million, yet the company missed its guida...
- Company missed its guidance for the quarter, CEO Joe Mastrangelo takes responsibility, but demand remains intact.
- Record revenue growth: Q4 revenue $58 million, FY 2025 revenue $114.2 million, roughly 7x year-over-year growth.
- Backlog and bookings: $701 million backlog at year end, bookings of ~1.1 GWh across eight customers and nine projects in Q4, and $240 million in new orders during the quarter.
- +13 more takeaways
Evolv Technology Fourth Quarter 2025 Earnings Call - Direct fulfillment fuels revenue and RPO growth, but trims near-term gross margins
Evolv closed 2025 with clear top-line momentum and a refreshed business mix. Q4 revenue was $38.5 million, up 32% year-over-year, and full-year revenue reached $145.9 million, up 40%. ARR finished at ...
- Q4 2025 revenue $38.5 million, up 32% year-over-year; full-year revenue $145.9 million, up 40% year-over-year.
- ARR at year-end 2025 was $120.5 million, up 21% year-over-year, with management expecting ARR growth to accelerate in 2026.
- RPO increased to $293.4 million, a 13% year-over-year gain, reflecting Gen2 upgrades and multiyear subscription terms.
- +15 more takeaways